Menu
x
Investors & Newsroom
Culture & Careers
Who we are
Who we are
Overview
Pioneers In Gene Therapy
Mission & Values
Management Team
Board of Directors
Science & innovation
Science & innovation
Overview
What is AAV Gene Therapy?
NAV® Technology Platform
Partners & Licensees
Manufacturing
Publications
Therapeutic pipeline
Therapeutic pipeline
Overview
ABBV-RGX-314 for Retinal Diseases
RGX-202 for Duchenne
RGX-121 for MPS II (Hunter Syndrome)
Patients & families
Patients & families
Overview
Why Gene Therapy?
Wet AMD
Duchenne
MPS II
Expanded Access
Search
Investors & Newsroom
Culture & Careers
Media
Presentation & Publications
Suprachoroidal Delivery of Investigational Surabgene Lomparvovec (Sura-vec
*
, ABBV-RGX-314): Results in NPDR at 2.5 Years
David S. Boyer, MD, Retina-Vitreous Associates Medical Group